Advanced Plant Pharmaceuticals, Inc. Appoints Dr. Gerard Armand as Director of Clinical Research and Manufacturing.

Business Editors

TEANECK, N.J.--(BUSINESS WIRE)--June 12, 2003

Advanced Plant Pharmaceuticals, Inc. (OTCBB:APPI), a company that utilizes whole plants through a proprietary (patent pending) manufacturing process to develop all natural dietary supplements, has announced the appointment of Dr. Gerard Armand as Director of Clinical Research and Manufacturing for the Company.

For nearly thirty years, Dr. Armand has worked as a researcher in the areas of chemistry, biochemistry and physiopathology. Dr. Armand began his career at the University of Chicago in the early 1960's where he was involved in the isolation and structural characterization of heparan sulfate and dermatan sulfate from skin fibroblasts and from urine derived from patients with "Hurler Syndrome ", a form of mucopolysaccharidoses. Dr. Armand received his PhD. from the University of Salford, England in 1971. His thesis was devoted toward the effect of ionizing radiation on biological macromolecules and the radiation protection conferred on their ionic complexes as a result of inter-molecular energy transfer mechanism. His postdoctoral research associate years were spent at Harvard Medical School, developing for the first time a procedure for isolating heparin species of low and high anticoagulant activities from commercially available pharmaceutical heparin preparations.

In 1978, Dr. Armand joined the faculty of Medicine at Columbia University. For fifteen years, as a Principal Investigator, he received research grants from both the National Institute of Health (NIH) and private foundations to carry out independent studies on medical problems ranging from eye to arthritic and pulmonary diseases. In 1985, to gain insight into the biotech industry, Dr. Armand spent a year at Genzyme Corporation, Boston, Mass. As a senior scientist at Genzyme, he worked on developing a commercial process for producing pharmaceutical grades of hyaluronic acid for the orthopedic and ophthalmic niche market. Dr. Armand's duties for APPI will be to consult and give advice to the Company on matters pertaining to clinical research, quality control, manufacturing existing products and developing new products.

For more information on APPI, please visit the Company's Web site at www.advancedplantpharm.com

FORWARD LOOKING STATEMENTS:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.